Search Result

Results for "

LDL receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (7) Autophagy (5) Biochemical Assay Reagents (3) CDK (1) Cytochrome P450 (1) Endogenous Metabolite (1) FXR (2) Histone Methyltransferase (1) HMG-CoA Reductase (HMGCR) (5) Isotope-Labeled Compounds (1) LDLR (3) LXR (1) MDM-2/p53 (1) Mitophagy (5) nAChR (2) PPAR (1) RAR/RXR (1) ROR (2) SARS-CoV (1) Ser/Thr Protease (10) Thyroid Hormone Receptor (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (11) Endocrinology (1) Infection (1) Inflammation/Immunology (2) Metabolic Disease (15) Neurological Disease (5)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	Ser/Thr Protease	Cardiovascular Disease
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .

HY-P99626

Frovocimab LY 3015014	Ser/Thr Protease	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-125544

LY 295427 Agisterol	LDLR	Metabolic Disease
LY 295427 is a **LDL receptor** modulator and a hypocholesterolemic agent. LY 295427 derepresses the transcription of the LDLR (LDL Receptor). LY 295427 can be used for hypercholesterolemia research .

HY-P99552

Tafolecimab IBI-306	Ser/Thr Protease	Cardiovascular Disease
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .

HY-147279

Milpocitide

LDLR Others

Milpocitide is a low-density lipoprotein receptor (human LDL receptor, LDLR), (293-333)-peptide fragment (EGF-like domain 1) .

Milpocitide	LDLR	Others
Milpocitide is a low-density lipoprotein receptor (human LDL receptor, LDLR), (293-333)-peptide fragment (EGF-like domain 1) .

HY-N2339

Cholesteryl behenate 1 Publications Verification Cholesteryl docosanoate; Cholesterol behenate	Endogenous Metabolite	Metabolic Disease
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.

HY-P99822

Recaticimab SHR-1209	Ser/Thr Protease	Metabolic Disease
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia .

HY-12402

SBC-115076 1 Publications Verification	Ser/Thr Protease	Cardiovascular Disease
SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism .

HY-148758

PCSK9-IN-13	Ser/Thr Protease	Metabolic Disease
PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC₅₀ of 537 nM .

HY-P1050

COG 133	nAChR	Neurological Disease Inflammation/Immunology
COG 133 is a fragment of Apolipoprotein E (APOE) peptide. COG 133 competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 is also a nAChR antagonist with an IC₅₀ of 445 nM .

HY-P1050A

COG 133 TFA 1 Publications Verification	nAChR	Neurological Disease Inflammation/Immunology
COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC₅₀ of 445 nM .

HY-157434

PCSK9-IN-23	Ser/Thr Protease	Cardiovascular Disease
PCSK9-IN-23 (compound 5C) is a potent PCSK9 inhibitor. PCSK9-IN-23 blocks PCSK9 secretion from HepG2 cells, significantly increases LDL receptor (LDLR) expression .

HY-101529

Imanixil HOE-402(free base)	LDLR	Cardiovascular Disease
Imanixil (HOE-402 free base) is an inducer of the LDL receptor (LDLR). Imanixil (HOE-402 free base) is also a potent cholesterol-lowering compound, which inhibits very low density-lipoprotein (VLDL) production, and consequently attenuates atherosclerosis development .

HY-10473

Eprotirome KB2115	Thyroid Hormone Receptor	Metabolic Disease Endocrinology
Eprotirome (KB2115) is a liver-selective *thyroid hormone receptor* (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα*. Eprotirome reduces low-density lipoprotein (LDL*) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .

HY-130245

PCSK9 degrader 1	Ser/Thr Protease	Metabolic Disease
PCSK9 degrader 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to PCSK9 with a K_i of 107 nM. PCSK9 degrader 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor .

HY-B0144AS1

Pitavastatin-d5 sodium NK-104-d₅ sodium	Apoptosis HMG-CoA Reductase (HMGCR) Mitophagy Autophagy	Metabolic Disease Cancer
Pitavastatin-d₅ (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.

HY-153452

PCSK9-IN-16	Ser/Thr Protease	Cardiovascular Disease
PCSK9-IN-16 is a potent PCSK9 inhibitor. PCSK9-IN-16 is extracted from patent WO2020150474, example 87, has the potential for hypercholesterolemia and other cardiovascular diseases research .

HY-126726

KOdiA-PC	Biochemical Assay Reagents	Others
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.

HY-114294A

DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium	Biochemical Assay Reagents	Metabolic Disease
DL-3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) disodium is a disodium salt compound of HMG-CoA, is a intermediate of terpenes and ketone bodies. DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium also involves in ester metabolism in vivo, as a precursor for cholesterol synthesis, and regulates cholesterol synthesis by coupling **LDL receptor** .

HY-10626

T0901317 Maximum Cited Publications 22 Publications Verification	LXR FXR ROR Apoptosis	Cardiovascular Disease Metabolic Disease Cancer
T0901317 is an orally active and highly selective LXR agonist with an EC₅₀ of 20 nM for LXRα . T0901317 activates FXR with an EC₅₀ of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with K_i values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .

HY-B0144A

Pitavastatin 4 Publications Verification NK-104	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-B0144B

Pitavastatin sodium NK-104 sodium	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin (NK-104) sodium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin sodium inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin sodium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin sodium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-152223

PCSK9-IN-11	Ser/Thr Protease	Cardiovascular Disease
PCSK9-IN-11 (compound 5r) is a potent and orally active PCSK9 inhibitor. PCSK9-IN-11 exhibits PCSK9 transcriptional inhibitory activity in HepG2 cells, with an IC₅₀ of 5.7 μM. PCSK9-IN-11 increases LDL receptor (LDLR) protein level. PCSK9-IN-11 can be used for atherosclerosis research .

HY-B0144S

Pitavastatin-d4 hemicalcium NK-104-d₄ hemicalcium; Pitavastatin-d₄ hemicalcium	Isotope-Labeled Compounds HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Metabolic Disease Cancer
Pitavastatin-d₄ (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].

HY-B0144

Pitavastatin Calcium 4 Publications Verification NK-104 hemicalcium; Pitavastatin hemicalcium	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-P1997

Ferrichrome Iron-free Desferrichrome; DFC; N-Desferriferrichrome	Biochemical Assay Reagents	Others
Ferrichrome is a hydroxamate siderophore produced by various fungi, including U. sphaerogena, that facilitates iron chelation and uptake by these organisms. It can be used as a heterosiderophore by bacteria, including Pseudomonas aeruginosa and Vibrio parahaemolyticus. Ferrichrome (0.8 μM) inhibits concanavalin A-induced proliferation of mouse spleen monocytes and reduces the number of concanavalin A-stimulated CD4+ T cells expressing IL-2 receptor. It also inhibits the heme-catalyzed oxidation of LDL by hydrogen peroxide in a concentration-dependent manner.

HY-163436

F44-A13	FXR Cytochrome P450 RAR/RXR PPAR ROR	Metabolic Disease
F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC₅₀ value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders .

HY-101563

GSK3326595 10+ Cited Publications EPZ015938	Histone Methyltransferase SARS-CoV MDM-2/p53 CDK Apoptosis	Infection Cancer
GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma .

Cat. No.	Product Name	Type

HY-126726

KOdiA-PC	Biochemical Assay Reagents
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.

KOdiA-PC

Biochemical Assay Reagents

Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.

HY-114294A

DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium	Biochemical Assay Reagents
DL-3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) disodium is a disodium salt compound of HMG-CoA, is a intermediate of terpenes and ketone bodies. DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium also involves in ester metabolism in vivo, as a precursor for cholesterol synthesis, and regulates cholesterol synthesis by coupling **LDL receptor** .

Cat. No.	Product Name	Target	Research Area

HY-P1050A

COG 133 TFA 1 Publications Verification	nAChR	Neurological Disease Inflammation/Immunology
COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC₅₀ of 445 nM .

HY-P1997

Ferrichrome Iron-free Desferrichrome; DFC; N-Desferriferrichrome	Biochemical Assay Reagents	Others
Ferrichrome is a hydroxamate siderophore produced by various fungi, including U. sphaerogena, that facilitates iron chelation and uptake by these organisms. It can be used as a heterosiderophore by bacteria, including Pseudomonas aeruginosa and Vibrio parahaemolyticus. Ferrichrome (0.8 μM) inhibits concanavalin A-induced proliferation of mouse spleen monocytes and reduces the number of concanavalin A-stimulated CD4+ T cells expressing IL-2 receptor. It also inhibits the heme-catalyzed oxidation of LDL by hydrogen peroxide in a concentration-dependent manner.

Cat. No.	Product Name	Target	Research Area

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	Ser/Thr Protease	Cardiovascular Disease
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .

HY-P99822

Recaticimab SHR-1209	Ser/Thr Protease	Metabolic Disease
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia .

HY-P99626

Frovocimab LY 3015014	Ser/Thr Protease	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-P99552

Tafolecimab IBI-306	Ser/Thr Protease	Cardiovascular Disease
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .

Cholesteryl behenate 1 Publications Verification Cholesteryl docosanoate; Cholesterol behenate	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.

Species:	Human (4) Mouse (3) Cynomolgus (1)
Tag:	His (8) Avi (2)
Source:	HEK293 (8)

Cat. No.	Compare	Product Name	Species	Source

HY-P70235

	LDLR Protein, Human (HEK293, His) 1 Publications Verification rHuLow-density lipoprotein receptor/LDLR, His; Low-Density Lipoprotein receptor; LDL receptor; LDLR	Human	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (HEK293, His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-6*His labeled tag. The total length of LDLR Protein, Human (HEK293, His) is 767 a.a., with molecular weight of 99-135 kDa.

HY-P700860

	LDLR Protein, Human (HEK293, Avi-His) LDLR; FHC; LDL R; LDL receptor; LDLCQ2; FH	Human	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (HEK293, Avi-His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of LDLR Protein, Human (HEK293, Avi-His) is 767 a.a., with molecular weight of 110-130 kDa.

HY-P77735

	LDLR Protein, Cynomolgus (HEK293, His) LDLR; FHC; LDL R; LDL receptor; LDLCQ2; FH	Cynomolgus	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived LDLR protein, expressed by HEK293 , with C-His labeled tag. The total length of LDLR Protein, Cynomolgus (HEK293, His) is 767 a.a., with molecular weight of 115-130 kDa.

HY-P73838

	LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) Low-density lipoprotein receptor; LDLR; LDL receptor	Mouse	HEK293
	LDLR Protein crucially binds to LDL, transporting cholesterol through endocytosis. Clustering into clathrin-coated pits initiates internalization. Interactions with DAB2, LDLRAP1, ARRB1, SNX17, and immature PCSK9 contribute to its functional versatility. The NPXY motif interaction is impaired by tyrosine phosphorylation. LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) is the recombinant mouse-derived LDLR protein, expressed by HEK293 , with C-His labeled tag and A23V, C27G mutation. The total length of LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) is 790 a.a., with molecular weight of ~85.7 kDa.

HY-P72392

	LDLR Protein, Human (Biotinylated, HEK293, Avi-His) Low-Density Lipoprotein receptor; LDL receptor; LDLR	Human	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (Biotinylated, HEK293, Avi-His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of LDLR Protein, Human (Biotinylated, HEK293, Avi-His) is 767 a.a., with molecular weight of 95-140 kDa.

HY-P73272

	LDLR Protein, Mouse (HEK293, His) Low-density lipoprotein receptor; LDLR; LDL receptor	Mouse	HEK293
	LDLR Protein crucially binds to LDL, transporting cholesterol through endocytosis. Clustering into clathrin-coated pits initiates internalization. Interactions with DAB2, LDLRAP1, ARRB1, SNX17, and immature PCSK9 contribute to its functional versatility. The NPXY motif interaction is impaired by tyrosine phosphorylation. LDLR Protein, Mouse (HEK293, His) is the recombinant mouse-derived LDLR protein, expressed by HEK293 , with C-His labeled tag. The total length of LDLR Protein, Mouse (HEK293, His) is 769 a.a., with molecular weight of ~98-130 kDa.

HY-P71180

	OLR1 Protein, Human (HEK293, His) Oxidized Low-Density Lipoprotein receptor 1; Ox-LDL receptor 1; C-Type Lectin Domain Family 8 Member A; Lectin-Like Oxidized LDL receptor 1; LOX-1; Lectin-Like oxLDL receptor 1; hLOX-1; Lectin-Type Oxidized LDL receptor 1; OLR1; CLEC8A; LOX1	Human	HEK293
	OLR1 Protein, a receptor on vascular endothelial cells, plays a key role in recognizing, internalizing, and degrading oxidatively modified low-density lipoprotein (oxLDL). As a marker of atherosclerosis, oxLDL induces vascular endothelial cell activation, leading to pro-inflammatory responses, oxidative conditions, and apoptosis. OLR1's association with oxLDL activates NF-kappa-B, contributing to pro-atherogenic responses such as reduced nitric oxide release, monocyte adhesion, and apoptosis. Beyond oxLDL, it serves as a receptor for HSP70, participating in cell-mediated antigen cross-presentation and functioning as a leukocyte-adhesion molecule in inflammation. Additionally, OLR1 recognizes AGE products, activated platelets, monocytes, apoptotic cells, and bacteria. OLR1 Protein, Human (HEK293, His) is the recombinant human-derived OLR1 protein, expressed by HEK293, with C-6*His labeled tag. The total length of OLR1 Protein, Human (HEK293, His) is 213 a.a., with molecular weight of 30-35 kDa.

HY-P77986

	LOX-1/OLR1 Protein, Mouse (HEK293, His) Ox-LDL receptor 1; LOX-1; CLEC8A; LOX1; OLR1; LOXIN; SR-E1; SCARE1; SLOX1	Mouse	HEK293
	The LOX-1/OLR1 protein is a receptor on vascular endothelial cells that promotes the recognition, internalization, and degradation of oxidatively modified low-density lipoprotein (oxLDL). This process is indicative of atherosclerosis and triggers endothelial cell activation, pro-inflammatory responses, oxidative conditions, and apoptosis. LOX-1/OLR1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived LOX-1/OLR1 protein, expressed by HEK293 , with N-His labeled tag. The total length of LOX-1/OLR1 Protein, Mouse (HEK293, His) is 304 a.a., with molecular weight of 55-63 kDa.

Cat. No.	Product Name	Application	Reactivity

HY-P81109

LDLR Antibody LDLR_HUMAN; Low-density lipoprotein receptor; LDL receptor; FH; FHC; FHCL1; LDLCQ2; low density lipoprotein receptor	WB; ELISA; Flow-Cyt; ICC	Human, Mouse(predicted: Rat, Dog, Pig, Cow, Horse, Rabbit, Guinea Pig)
LDLR Antibody is an unconjugated, approximately 92 kDa, rabbit-derived, anti-LDLR polyclonal antibody. LDLR Antibody can be used for: WB, ELISA, Flow-Cyt, ICC expriments in human, mouse, and predicted: rat, dog, pig, cow, horse, rabbit, guinea pig background without labeling.

HY-P81172

LOX 1 Antibody Lectin-type oxidized LDL receptor 1; OLR1; lectin-like low density lipoprotein receptor-1; Oxidized low-density lipoprotein receptor 1; Ox-LDL receptor 1; Lectin-like oxidized LDL receptor 1; Lectin-like oxLDL receptor 1; LOX-1; BLOX1; Contains: Oxidized low-density lipoprotein receptor 1, soluble form A; Oxidized low-density lipoprotein receptor 1, soluble form B; OLR1_HUMAN.	WB; ELISA; IHC-P; IHC-F; IF	Human, Rat, Rabbit(predicted: Mouse, Cow)
LOX 1 Antibody is an unconjugated, approximately 31/50 kDa, rabbit-derived, anti-LOX 1 polyclonal antibody. LOX 1 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, rat, rabbit, and predicted: mouse, cow background without labeling.

HY-P80758

MSR1 Antibody Macrophage scavenger receptor types I and II; Macrophage acetylated LDL receptor I and II; Scavenger receptor class A member 1; CD204; MSR1; SCARA1	WB	Human, Mouse, Rat
MSR1 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 50 kDa, targeting to MSR1. It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

LDL receptor

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products